http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Strength and structural barrier function of steel channel-reinforced concrete composite slabs
Katsuhiko Emori 국제구조공학회 2003 Steel and Composite Structures, An International J Vol.3 No.4
This paper reports on the development of a new composite slab system that uses a large- lipped steel channel and reinforced concrete. The advantages of this new system are that it serves as both a structural unit and an unsupported form and it has a secondary structural barrier function. A concrete pouring test was carried out for the large-lipped steel channel. Full-scale tests were carried out to assess the flexural strengthdeformation characteristics and structural mechanics of the composite slab. The barrier mechanics of the steel channel concrete element (referred to as the SC subunit) of the composite slab are examined. The test results indicate that the new composite slab has excellent strength, ductility characteristics, and a structural barrier function in its SC subunit that is highly effective against severe loading.
Atsushi Nakajima,Mio Fujimaki,Yuki Arai,Kento Emori 대한소화기 기능성질환·운동학회 2022 Journal of Neurogastroenterology and Motility (JNM Vol.28 No.3
Background/AimsElobixibat, an ileal bile acid transporter (apical sodium-dependent bile acid transporter) inhibitor, was recently launched in Japan for the treatment of chronic idiopathic constipation. We conducted an interim analysis of post-marketing surveillance to evaluate the safety and efficacy of elobixibat in elderly patients with chronic constipation and compared the efficacy according to administration time. MethodsSafety and efficacy outcomes were evaluated through patient interviews for 4 weeks. ResultsAdverse drug reactions (ADRs) were observed in 5.24% of the 1049 patients analyzed; diarrhea (2.19%) and abdominal pain (1.81%) were the most common. A serious ADR of death was reported in one patient (0.10%). The incidence of ADRs in the ≥ 65-year old or ≥ 75-year-old subpopulation was similar to that in the total patient population. Mean bowel movements per week significantly increased from 2.9 ± 2.5 at baseline to 5.0 ± 3.1 (P < 0.001) at Week 2 and 5.3 ± 2.6 (P < 0.001) at Week 4. The mean Bristol Stool Form Scale score significantly increased from 2.3 ± 1.4 at baseline to 3.8 ± 1.3 (P < 0.001) at Week 2 and 3.9 ± 1.1 at Week 4 (P < 0.001). Bowel movements significantly increased in the elderly population and subpopulations receiving elobixibat before breakfast, lunch, or dinner. The median time to bowel movement was 5 hours. ConclusionThe results suggested that elobixibat was well-tolerated and efficacious in elderly patients with chronic constipation and can be administered before any meals.